The effectiveness of interferon-alpha subtypes alternation for metastasis from renal cell carcinoma.
|
| Abstract |
Interferon-alpha (IFN-α) has been used in systemic treatment for metastatic renal cell carcinoma (mRCC). IFN-α has at least 14 subtypes, each of which has different biological activity. There have been reports that mRCC resistant to an IFN-α treatment responded to another IFN-α subtype. This study was performed to evaluate the effectiveness of alternation of different IFN-α subtypes for mRCC that did not respond to initial IFN-α treatment. In our department and associated institutions, alternating therapy of IFN-α was provided for 15 initial IFN-α refractory mRCC cases from June 2005 to September 2008. Among the 15 patients, the effects of alternating IFN-α therapy were as follows: complete response (CR), 0 cases; partial response (PR), 1 case; stable disease (SD), 3 cases; progressive disease (PD), 11 cases. The response rate (CR+PR) was 7% and disease control rate (CR+PR+SD) was 27%. No severe side effects were observed in any of these cases. The PR case is still in PR 21 months after alternating IFN-α therapy. Among the three SD cases, one has continued SD for 14 months and the other for 12 months. Alternating IFN-α therapy for mRCC can be attempted even if other cytokines are not effective.
|
|---|---|
| Authors | Yoshifumi Kadono, Sotaro Miwa, Takashi Shima, Hiroyuki Konaka, Atsushi Mizokami, Satoshi Yotsuyanagi, Akio Hirata, Yasukazu Takase, Toshiaki Sugata, Masayoshi Shimamura, Mikio Namiki |
| Journal | Biomedical research (Tokyo, Japan) (Biomed Res) Vol. 33 Issue 6 Pg. 323-8 (Dec 2012) ISSN: 1880-313X [Electronic] Japan |
| PMID | 23268955 (Publication Type: Journal Article) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!